نتایج جستجو برای: decitabine

تعداد نتایج: 2165  

2015
Deepti Warad Mira A. Kohorst Sadaf Altaf Michael B. Ishitani Shakila Khan Vilmarie Rodriguez Amulya A. Nageswara Rao

Acute appendicitis in children with acute leukemia is uncommon and often recognized late. Immunocompromised host state coupled with the importance of avoiding treatment delays makes management additionally challenging. Leukemic infiltration of the appendix though rare must also be considered. Although successful conservative management has been reported, surgical intervention is required in mos...

2016
Simone Jueliger John Lyons Sara Cannito Illar Pata Pille Pata Marianna Shkolnaya Oriana Lo Re Marion Peyrou Francesc Villarroya Valerio Pazienza Francesca Rappa Francesco Cappello Mohammad Azab Pietro Taverna Manlio Vinciguerra

Hepatocellular carcinoma (HCC) is a deadly malignancy characterized at the epigenetic level by global DNA hypomethylation and focal hypermethylation on the promoter of tumor suppressor genes. In most cases it develops on a background of liver steatohepatitis, fibrosis, and cirrhosis. Guadecitabine (SGI-110) is a second-generation hypomethylating agent, which inhibits DNA methyltransferases. Gua...

Journal: :JAMA oncology 2015
Yue Han Yaqiong Tang Jia Chen Jianying Liang Chunmei Ye Changgeng Ruan Depei Wu

Low-DoseDecitabine for PatientsWith Thrombocytopenia Following Allogeneic Hematopoietic StemCell Transplantation: A Pilot Therapeutic Study Isolatedthrombocytopeniaafterhematopoietic stemcell transplantation (HSCT) isdefinedasconsistently lowplatelet counts after transplantation,withrecoveryofallotherperipheralblood cell lines.1 It represents a challenging clinical problem because itoften leads...

2018
Meng-Meng Ji Yao-Hui Huang Jin-Yan Huang Zhao-Fu Wang Di Fu Han Liu Feng Liu Christophe Leboeuf Li Wang Jing Ye Yi-Ming Lu Anne Janin Shu Cheng Wei-Li Zhao

Due to heterogeneous morphological and immunophenotypic features, approximately 50% of peripheral T-cell lymphomas are unclassifiable and categorized as peripheral T-cell lymphomas, not otherwise specified. These conditions have an aggressive course and poor clinical outcome. Identification of actionable biomarkers is urgently needed to develop better therapeutic strategies. Epigenetic alterati...

2012
Alfonso Quintás-Cardama Farhad Ravandi Theresa Liu-Dumlao Mark Brandt Stefan Faderl Sherry Pierce Gautam Borthakur Guillermo Garcia-Manero Jorge Cortes Hagop Kantarjian

We reviewed the outcome of 671 patients 65 years of age or older with newly diagnosed acute myeloid leukemia (AML) treated at our institution between 2000 and 2010 with intensive chemotherapy (n 557) or azacitidineor decitabinebased therapy (n 114). Both groups were balanced according to cytogenetics and performance status. The complete response rates with chemotherapy and epigenetic therapy we...

2015
Hyun Ae Jung Chi Hoon Maeng Moonjin Kim Sungmin Kim Chul Won Jung Jun Ho Jang

Despite the efficacy of decitabine to myelodysplastic syndrome (MDS), there is a wide range of responses, and no definite predictive marker has been identified. This study aimed to describe the efficacy of decitabine and to identify potential predictors of response and survival in patients with MDS. We retrospectively analyzed clinical data of MDS patients at Samsung Medical Center between Augu...

2016
Elias Jabbour Hagop M Kantarjian Guillermo Garcia-Manero Jean-Pierre J Issa

Journal: :International journal of oncology 2008
Claudio Festuccia Giovanni Luca Gravina Anna Maria D'Alessandro Danilo Millimaggi Cristiana Di Rocco Vincenza Dolo Enrico Ricevuto Carlo Vicentini Mauro Bologna

One of the major obstacles in curing prostate cancer is the development of drug resistance. It is not only imperative to discover the molecular basis of resistance but also to find therapeutic agents that can disrupt the resistant pathways. Tumor necrosis factor TNF-related apoptosis-inducing ligand TRAIL-like ligands or agonist TRAIL-receptor monoclonal antibodies have entered phase I and II c...

Journal: :Cancer Research 2021

Abstract Hypomethylating agents (HMA) have become the backbone of nonintensive acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) treatment, also by virtue their activity in patients with adverse genetics, for example, monosomal karyotypes, often losses on chromosome 7, 5, or 17. No comparable is observed cytarabine, a cytidine analogue without DNA-hypomethylating properties. As evidence...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید